EU Launches €225 Million Initiative to Accelerate Next-Generation Influenza Vaccine Development
Key Insights
The European Union has committed €225 million to advance next-generation flu vaccines (search) through clinical trials, representing the largest EU investment ever dedicated to accelerating innovative medical countermeasures.
This marks the first use of pre-commercial procurement by the European Commission to support vaccine candidates through clinical development, with contracts awarded to 10 organizations for 98-month development programs.
The initiative aims to develop vaccines that protect against broader influenza (search) variants, can be rapidly adapted for pandemic strains, and offer alternative administration methods including nasal sprays, oral doses, and skin patches.
The European Union has launched an unprecedented €225 million investment to accelerate the development of next-generation influenza (search) vaccines, marking the largest EU commitment ever dedicated specifically to innovative medical countermeasures. The initiative represents a significant shift in European health policy, utilizing pre-commercial procurement for the first time to advance vaccine candidates through clinical trials.
Revolutionary Procurement Approach
The European Commission has awarded contracts to 10 organizations, including Nivi Development P/S (search), Ethris GmbH, Statens Serum Institut, Vismederi Srl (search), Stichting European Clinical Research Alliance On Infectious Diseases, Bavarian Nordic AS (search), Evonik Operations GmbH, IDT Biologika GmbH, Sanofi Pasteur SA (search), and Sclavo Vaccines Association (search). These contracts, signed in February 2026, will run for 98 months and cover non-clinical development, clinical trial phases I, II and III, as well as pre-market regulatory preparation.
Under the pre-commercial procurement (PCP) model, public authorities procure research and development services for solutions not yet available on the market. Multiple contractors are selected competitively and progress through phased development, with participation narrowed as projects move from early-stage research to more complex clinical stages. The mechanism is designed to ensure strict safety, quality and efficacy standards while sharing development risks between the public sector and industry.
Addressing Critical Vaccine Development Challenges
The policy initiative comes against the backdrop of persistent scientific and structural challenges in influenza (search) vaccine development. A 2025 review published in Vaccine concludes that while progress has been made, many critical milestones remain unresolved. According to the authors, significant work remains to identify robust correlates of protection, better understand immune imprinting, and induce durable and broadly protective immunity, including at the mucosal level.
The review notes that some milestones have seen limited or no progress due to scientific complexity, resource constraints and the need for sustained political commitment. Of 93 roadmap milestones assessed, the majority remain in progress rather than completed. The pipeline of next-generation candidates exists, but advancing them through full clinical development and licensure requires sustained coordination, risk-sharing and long-term investment.
Next-Generation Vaccine Features
The vaccines supported under the scheme are intended to protect against a broader range of influenza (search) variants, be adapted rapidly if a pandemic strain emerges and be easier to administer, including via nasal sprays, oral doses or skin patches. Flu viruses evolve constantly, which means vaccine technology must keep pace to maintain effectiveness across diverse viral strains.
By widening the development pipeline and investing in scalable production and alternative delivery methods, the Commission aims to strengthen Europe's ability to respond at scale when outbreaks intensify. The funding will support vaccines designed to be rapidly scaled up in emergencies, addressing both preparedness and accessibility concerns.
Strategic Impact and Policy Implications
"With an EU investment of €225 million – the largest ever dedicated to accelerating access to innovative medical countermeasures – we are advancing the development of next-generation flu vaccines (search)," stated Hadja Lahbib, European Commissioner for Equality, Preparedness and Crisis Management. "Innovation is at the heart of preparedness. This funding will unlock cutting-edge technologies, including more accessible and diverse vaccine administration methods, ensuring that effective vaccine options reach underserved and vulnerable groups."
The initiative is positioned as both a pandemic preparedness measure and an industrial strategy tool. By supporting both SMEs and established vaccine manufacturers, the programme aims to strengthen Europe's pharmaceutical ecosystem and enhance long-term competitiveness in vaccine development and production.
Regulatory and Development Framework
The action is financed by the Commission's Health Emergency Preparedness and Response Authority (search) under the EU4Health programme and managed by the European Health and Digital Executive Agency (search). The pre-commercial procurement model funds research and development under favourable terms to foster a more inclusive market, particularly for small and medium enterprises.
Regulatory pathways for licensing broadly protective vaccines require further clarification, including the possible use of alternative clinical evaluation strategies. The initiative aims to support innovations that might otherwise stall without public intervention, particularly in areas where scientific uncertainty, high development costs and unclear commercial returns may deter purely private investment.
By combining scientific ambition, regulatory risk-sharing and industrial scale-up, the €225 million initiative signals a shift toward more structured public demand for breakthrough medical countermeasures, reinforcing Europe's resilience against future influenza (search) outbreaks or pandemics.